Navigation Links
RxElite Registration Statement Suspended
Date:1/4/2008

MERIDIAN, Idaho, Jan. 4 /PRNewswire-FirstCall/ -- RxElite, Inc. (OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today the suspension of their registration statement covering the resale of 53,747,555 shares. The suspension is permitted by the Securities and Exchange Commission in certain cases. The company requested this suspension to protect investors due to material non-public information relating to an acquisition. The Company will release information regarding the acquisition as soon as practical. The suspension of this registration statement is allowable for up to 90 days.

About RxElite, Inc.

RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.

Contacts:

Corporate Information

Ph: (208) 288-5550

Toll Free: (800) 414-1901

Fax: (208) 288-1191

Investor Relations

Charlie Forshee, 215-885-4981

investorrelations@rxelite.com

Segue Ventures LLC


'/>"/>
SOURCE RxElite, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. RxElite Files Registration Statement with Securities and Exchange Commission
2. RxElite Announces 3rd Quarter Financials Conference Call
3. RxElite Registration Statement Declared Effective by Securities and Exchange Commission
4. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
5. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
6. Gentiva(R) Health Services Files Universal Shelf Registration Statement
7. PA Governors Occupational Safety and Health Conference Still Accepting Registrations
8. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
9. Pearson Introduces Smart Technology for Collecting Patient Registration Information
10. FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
11. HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, ... is a benign bony lump located on the forehead usually attributed to a facial ... sight and pain. Dr. Shah has discovered an approach that is minimally invasive. He ...
(Date:4/21/2017)... ... 2017 , ... Dudnyk has announced the launch of its new brand identity, ... potential of specialty and orphan brands can only be achieved when the needs and ... Effect is at the heart of a true partnership between our agency and our ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology: